Mutational analysis of selected high-grade malignancies in a premenopausal gynecologic cancer population: a potential for targeted therapies?

Table 3 Neuroendocrine Profile

n = 4					Genes associated with this histologic type^b
Age					APC	P16
Range	13–40				FHIT	PTEN
Mean	29				FGFR1	RB
Median	32				KRAS	SOX
BMI					MCC	TP53
Range	21.5–39.5				MEN-2
Mean	29.1				MYCL
Median	27.7
Survival
Range	189–596
Mean	366
Median	339.5
		Chemo	Rad	Alive	Novel Targets	Profiles
Location
Ovary	2 (50%)	Plat/Etoposide	0	1 (50%)	AKAP9 (1) ASXL1 (1) MBD1 (1) ALK (1) GPR124 (1) KMT2D (1)	AKAP9, ASXL1, MBD1 (1) ALK, GPR124, KMT2D (1)^a
Cervix	1 (25%)	Plat/Etoposide	1	1 (100%)	AKAP9 (1) ASXL1 (1) CMPK1 (1)	AKAP9, ASXL1, CMPK1 (1)
Endometrial	1 (25%)	Carbo/Taxol	1	0 (0%)	ROS1 (1) ALK (1) ERBB3 (1) GPR124 (1) KMT2D (1) NTRK1 (1)	ROS1, ALK, ERBB3, GPR124, KMT2D, NTRK1 (1)^a

^aindicates these profiles are associated with negative outcomes in our cohort; ^bdata and sources retrieved from http://cancer.sanger.ac.uk/cosmic